Search / Trial NCT06615921

A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Launched by TAKEDA · Sep 26, 2024

Trial Information

Current as of October 08, 2024

Not yet recruiting

Keywords

Drug Therapy

Description

This study will include two main periods of retrospective data collection from medical charts: the pre-index period and the post-index period. The index date is defined as the date of initiation of maribavir dosing, as documented in the medical records. The pre-index period covers the time from the transplant date to the index event, while the post-index period starts at the index event and ends at the date of chart abstraction, death, or loss to follow-up, whichever comes first.

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • * Aged greater than or equal to (\>=) 18 years at the time of consent or start of chart abstraction in case a consent waiver will be allowed as per local regulation.
  • * Received an HSCT/SOT.
  • * Diagnosed with CMV infection/disease any time after the HSCT/SOT date.
  • * Initiated maribavir at least 4 months before the chart abstraction date (or at time of Central Ethics Committee \[CEC\]/Local Ethics Committee \[LEC\] submission as per local regulation).
  • * Participants with hospital medical chart available, who signed an informed consent form before starting any study procedures (unless waiver is allowed as per local regulation).
  • Exclusion criteria:
  • * Participants who do not provide informed consent, where consent is required per country regulations.
  • * Participants who participated to Clinical Trials investigating maribavir.

About Takeda

Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.

Locations

Granada, , Spain

Madrid, , Spain

Ulm, , Germany

Santander, Cantabria, Spain

Montpellier, , France

Manchester, , United Kingdom

Bilbao, , Spain

Barcelona, , Spain

London, , United Kingdom

Geneva, , Switzerland

Greifswald, , Germany

Madrid, , Spain

Novi Sad, , Serbia

Strasbourg, , France

Paris, , France

Aachen, , Germany

Birmingham, , United Kingdom

Rotterdam, , Netherlands

Leipzig, , Germany

London, , United Kingdom

Southampton, , United Kingdom

Wurzburg, , Germany

Vienna, , Austria

Copenaghen, , Denmark

Bordeaux, , France

Dijon, , France

Lille, , France

Nice, , France

Paris, , France

Paris, , France

Toulouse, , France

Berlin, , Germany

Essen, , Germany

Hamburg, , Germany

Hannover, , Germany

Mainz, , Germany

Munich, , Germany

Roma, , Italy

Utrecht, , Netherlands

Belgrade, , Serbia

Las Palmas, , Spain

Cambridge, , United Kingdom

London, , United Kingdom

Newcastle, , United Kingdom

Nottingham, , United Kingdom

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0